UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi41

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of everolimus and exemestane for metastatic breast cancer patients: a real-life experience of three Oncology Departments

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi42

2017

Link zum Volltext

Verfügbarkeit prüfen

From the CLEOPATRA study to real life: preliminary results from the G.O.N.O. SUPER trial

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi28-vi29

2017

Link zum Volltext

Verfügbarkeit prüfen

Cardioprotection beyond the guidelines: the SAFE trial results

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Link zum Volltext

Verfügbarkeit prüfen

290P From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial

Annals of oncology, 2020-09, Vol.31, p.S358-S358

2020

Link zum Volltext

Verfügbarkeit prüfen

(R)-a-Lipoic acid for the treatment of peripheral neuropathy in breast cancer patients (BCP) receiving adjuvant (A) or neoadjuvant (N) paclitaxel (P)

Annals of oncology, 2016-09, Vol.27, p.iv76

2016

Link zum Volltext

Verfügbarkeit prüfen

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v118-v118

2019

Link zum Volltext

Verfügbarkeit prüfen

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30, p.v118

2019

Link zum Volltext

Verfügbarkeit prüfen

(R)-a-Lipoic acid reduces sensorial peripheral neurotoxicity in breast cancer patients receiving weekly paclitaxel

Annals of oncology, 2015-10, Vol.26, p.vi24

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract P5-21-29: Moving from the CLEOPATRA study to real life: Preliminary results from the G.O.N.O. SUPER trial

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P5-P5-21-29

2018

Link zum Volltext

Verfügbarkeit prüfen

Cardiac Safety Assessment of Adjuvant Nonpegylated Liposomal Doxorubicin (Npld) Plus Cyclophosphamide (C) Followed By Paclitaxel (P) in Elderly Breast Cancer (Ebc) Women

Annals of oncology, 2014-09, Vol.25, p.iv101

2014

Link zum Volltext

Verfügbarkeit prüfen

The role of transvaginal ultrasound in early diagnosis of tamoxifen-related endometrial cancer: An Italian experience

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.11021-11021

2007

Link zum Volltext

Verfügbarkeit prüfen

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine in combination with capecitabine in metastatic breast carcinoma: A phase I-II study

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.870-870

2005

Link zum Volltext

Verfügbarkeit prüfen

303PCARDIAC SAFETY ASSESSMENT OF ADJUVANT NONPEGYLATED LIPOSOMAL DOXORUBICIN (NPLD) PLUS CYCLOPHOSPHAMIDE (C) FOLLOWED BY PACLITAXEL (P) IN ELDERLY BREAST CANCER (EBC) WOMEN

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv101-iv101

2014

Link zum Volltext

Verfügbarkeit prüfen

Design of a pilot-scale microwave heated chemical vapor infiltration plant: An innovative approach

Journal of the European Ceramic Society, 2021-05, Vol.41 (5), p.3019-3029

2021

Link zum Volltext

Verfügbarkeit prüfen

Continental margin large-scale instability controlling the flank sliding of Etna volcano

Earth and planetary science letters, 2011-05, Vol.305 (1), p.57-64

2011

Link zum Volltext

Verfügbarkeit prüfen

Time and space scattered volcanism of Mt. Etna driven by strike-slip tectonics

Scientific reports, 2019-08, Vol.9 (1), p.12125-15, Article 12125

2019

Link zum Volltext

Verfügbarkeit prüfen

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2023-06, Vol.388 (22), p.2058-2070

2023

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the 2001 lava flow eruption of Mt. Etna from three-dimensional mapping

Journal of Geophysical Research - Earth Surface, 2007-06, Vol.112 (F2), p.F02029-n/a

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(45)

Publikationsform

Sprache

Englisch
(50)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cardiac safety of adjuvant non-pegylated liposomal doxorubicin combined with cyclophosphamide and followed by paclitaxel in older breast cancer patients

Efficacy and safety of everolimus and exemestane for metastatic breast cancer patients: a real-life experience of three Oncology Departments

From the CLEOPATRA study to real life: preliminary results from the G.O.N.O. SUPER trial

Cardioprotection beyond the guidelines: the SAFE trial results

417P New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study

290P From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial

(R)-a-Lipoic acid for the treatment of peripheral neuropathy in breast cancer patients (BCP) receiving adjuvant (A) or neoadjuvant (N) paclitaxel (P)

333P - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study

335P - Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study

(R)-a-Lipoic acid reduces sensorial peripheral neurotoxicity in breast cancer patients receiving weekly paclitaxel

Abstract P5-21-29: Moving from the CLEOPATRA study to real life: Preliminary results from the G.O.N.O. SUPER trial

Cardiac Safety Assessment of Adjuvant Nonpegylated Liposomal Doxorubicin (Npld) Plus Cyclophosphamide (C) Followed By Paclitaxel (P) in Elderly Breast Cancer (Ebc) Women

The role of transvaginal ultrasound in early diagnosis of tamoxifen-related endometrial cancer: An Italian experience

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

335PSafety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study

Gemcitabine in combination with capecitabine in metastatic breast carcinoma: A phase I-II study

303PCARDIAC SAFETY ASSESSMENT OF ADJUVANT NONPEGYLATED LIPOSOMAL DOXORUBICIN (NPLD) PLUS CYCLOPHOSPHAMIDE (C) FOLLOWED BY PACLITAXEL (P) IN ELDERLY BREAST CANCER (EBC) WOMEN

Bio-Based Packaging: Materials, Modifications, Industrial Applications and Sustainability

Design of a pilot-scale microwave heated chemical vapor infiltration plant: An innovative approach

Continental margin large-scale instability controlling the flank sliding of Etna volcano

Time and space scattered volcanism of Mt. Etna driven by strike-slip tectonics

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Analysis of the 2001 lava flow eruption of Mt. Etna from three-dimensional mapping

Suchergebnisse filtern